Download PDF
Hamostaseologie 1982; 02(03): 110-115
DOI: 10.1055/s-0038-1656573
Originalarbeiten
Schattauer GmbH

Aktivierte Prothrombinkomplexkonzentrate

K. Lechner
1   Aus der I. Medizinischen Universitätsklinik Wien (Vorstand: Prof. Dr. Dr. h. c. E. Deutsch) Abteilung für Hämatologie und Blutgerinnung
› Author Affiliations
Further Information

Publication History

Publication Date:
21 June 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • LITERATUR

  • 1 Abildgaard C. F., Britton M., Harrison J. Prothrombin complex concentrate (Konyne) in the treatment of hemophilic patients with factor VIII inhibitors. J. Pediat. 1976; 88: 200.
    CrossrefPubMedGoogle Scholar
  • 2 Abildgaard C. F., Penner J., Watson-Williams E. Anti-inhibitor coagulant complex (autoplex) for treatment of factor VIII inhibitors in hemophilia. Blood 1980; 56: 978.
    PubMedGoogle Scholar
  • 3 Aronson D. L., Bagley J. Preliminary characterisation of factor VIII bypassing coagulant. Ann. N. Y. Acad. Sci. 1981; 370: 291.
    CrossrefPubMedGoogle Scholar
  • 4 Aronstam A., Aston L., Wassef M., Hamad Z. New activated factor IX product in haemophilia. Lancet II 1980; 1294.
    PubMedGoogle Scholar
  • 5 Austen D. E. G., Lechner K., Rizza C. R., Rhymes I. L. A comparison of the Bethesda and new Oxford methods of factor VIII antibody assay. Thromb. Haemostas. 1982; 47: 72.
    PubMedGoogle Scholar
  • 6 Austen D. E., Rhymes I. L. A laboratory manual of blood coagulation. Blackwell Scientific; Oxford: 1975
    Google Scholar
  • 7 Barrowcliffe T. W., Kemball-Cook G., Gray E. Factor VIII inhibitor bypassing activity: A suggested mechanism of action. Thromb. Res. 1981; 21: 181.
    CrossrefPubMedGoogle Scholar
  • 8 Bloom A. L. Factor VIII inhibitors revisited. Brit. J. Haemat. 1981; 49: 319.
    CrossrefPubMedGoogle Scholar
  • 9 Breen F. A., Tullís J. L. Prothrombin concentrates in treatment of Christmas disease and allied disorders. JAMA 1969; 208: 1818.
    PubMedGoogle Scholar
  • 10 Buchanan G., Kevy S. Use of prothrombin complex concentrates in hemophiliacs with inhibitors: Clinical and laboratory studies. Pediatrics 1978; 62: 767.
    PubMedGoogle Scholar
  • 11 Elsinger F. Laboratory tests of activated prothrombin complex preparations. In: Mariani (ed.): The state of the Art of Managing hemophilia with factor VIII inhibitor. Praeger; New York: 1982
    Google Scholar
  • 12 Fekete L. F., Holst S. L., Peetom F., Deveber L. L. Auto-factor IX concentrate: a new therapeutic approach to treatment of haemophilia A patients with inhibitors. 14th Intern. Congress of Hematology; Brazil.: Abstr. No. 295 1972
    Google Scholar
  • 13 Fukui H., Fujimura Y., Takamashi Y., Mikami S., Yoshioka A. Laboratory evidence of DIC under FEIBA treatment of a hemophiliac patient with intracranial bleeding and high titre factor VIII inhibitor. Thromb. Res. 1981; 22: 177.
    CrossrefPubMedGoogle Scholar
  • 14 Hanna W. T., Madigan R. R., Miles M. A., Lange R. D. Activated factor IX complex in treatment of surgical cases of hemophilia A with inhibitors. Thromb. Haemost. 1981; 46: 638.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Hilgartner M. W., Aledort L. M., Knatterud G. L. Verbal report to the subcommittee on factor IX concentrates. 8th Intern. Congress of Thromb. and Haemost. Toronto; Canada, July: 1981
    Google Scholar
  • 16 Hoots W. K., Snyder M. S., McMillan C. S. Effects of activated prothrombin complex concentrates (APCC) for craniospinal haemorrhage in classic haemophiliacs with factor VIII inhibitors. Ped. Res. 1980; 14: 535.
    PubMedGoogle Scholar
  • 17 Hultin M. B. Activated clotting factors in factor IX concentrates. Blood 1979; 54: 1028.
    PubMedGoogle Scholar
  • 18 Kasper C. K. Thromboembolic complications. Thromb. Diath. Haemorr. 1975; 32: 492.
    PubMedGoogle Scholar
  • 19 Kasper C. K., Aledort L. M., Counts R. B. et al.: A more uniform measurement of factor VIII inhibitors. Thromb. Diath. Haemorr. 1975; 34: 869.
    PubMedGoogle Scholar
  • 20 Kasper C. K. Hemophilia Study Group: Effect of prothrombin complex concentrates on factor VIII inhibitor levels. Blood 1979; 54: 1358.
    PubMedGoogle Scholar
  • 21 Kazama M., Abe T. Analysis of the corrective effect of activated prothrombin complexes. Haemostasis 1981; 10: 215.
    PubMedGoogle Scholar
  • 22 Kingdon H. S., Hassell T. M. An animal model for evaluating the haemostatic effectiveness of factor VIII inhibitor bypassing materials. Clin. Res. 1980; 28: 769.
    PubMedGoogle Scholar
  • 23 Kurczynski E. M., Penner J. A. Activated prothrombin concentrate for patients with factor VIII inhibitors. New Engl. J. Med. 1974; 291: 164.
    CrossrefPubMedGoogle Scholar
  • 24 Lechner K. Differences in the immune response in hemophiliacs with acquired inhibitors. Workshop on Inhibitor to factor VIII and IX, Wien 48 1976
    Google Scholar
  • 25 Lechner K. Acquired inhibitors in nonhemophilic patients. (Review). Haemostatis 1974; 3: 65.
    PubMedGoogle Scholar
  • 26 Lechner K., Korninger Ch. Structure ,characteristics and natural history of factor VIII- and IX-inhibitors in non-hemophiliacs. In: Seligsohn et al. (eds.): »Haemophilia«. Castle House Publ. Ltd.; 1981: 87.
    Google Scholar
  • 27 Lechner K., Nowotny C., Krinninger B., Zegner M., Deutsch E. The effect of treatment with activated prothrombin complex concentrate (FEIBA) on factor VIII antibody level. Thromb. Haemost. 1978; 40: 478.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Lusher J. M., Shapiro S. S., Palascak J. E. et al.:Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. New Engl. J. Med. 303: 421 1980;
    CrossrefPubMedGoogle Scholar
  • 29 Mannucci P. M., Bader R., Ruggieri Z. M. Concentrates of clotting factor IX. Lancet I: 41 1976;
    PubMedGoogle Scholar
  • 30 Mannucci P. M., Federici A., Vigano S., Cattaneo M. Multiple dental extractions with a new prothrombin complex concentrate in two patients with factor VIII inhibitors. Thromb. Res. 1979; 15: 359.
    CrossrefPubMedGoogle Scholar
  • 31 Nowotny C., Lechner K., Niessner H., Thaler E. Effect in vivo administration of FEIBA on clotting tests. Dose-response relationship. Thromb. Haemost. 1979; 42: 199.
    PubMedGoogle Scholar
  • 32 Parry D. H., Bloom A. K. Failure of factor VIII inhibitor bypassing activity to secure haemostasis in hemophilia patients with antibodies. J. Clin. Pathol. 1978; 31: 1102.
    CrossrefPubMedGoogle Scholar
  • 33 Penner J. A. Therapeutic approaches to inhibitors: vitamin K-dependent factor concentrates. In: U. Seligsohn et al. (eds.): »Haemophilia« Castle House Publ. Ltd.; 97 1981
    Google Scholar
  • 34 Penner J. A., Abildgaard C. F. Ineffectiveness of certain commercial prothrombin complex concentrates in treatment of patients with inhibitors of factors VIII and IX. New Engl. J. Med. 1979; 300: 565.
    PubMedGoogle Scholar
  • 35 Penner J. A., Kelly P. E. Management of patients with factor VIII or IX inhibitors. Semin Thromb. Hemostas. 1975; 1: 386.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Pollock A., Lewis M. J. Factor VIII inhibitor bypassing activity. Lancet II: 43 1976;
    PubMedGoogle Scholar
  • 37 Rasche H., Bindewald H., Köhle W. et al. :Notfallbehandlung von Blutungskomplikationen bei Hemmkörper-Hämophihe mit aktivierten Prothrombinkomplexkon-zentraten. Dtsch. med. Wschr. 1977; 102: 319.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Seligsohn U., Kasper C. K., Osterud B., Rapaport S. Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979; 53: 828.
    PubMedGoogle Scholar
  • 39 Sjamsoedin L. J. M., Heijnen L., Mauser-Bunschoten E. P. et al. : The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII: a double-blind clinical trial. New Engl. J. Med. 1981; 305: 717.
    CrossrefPubMedGoogle Scholar
  • 40 Sonoda T., Solomon A., Krauss St., Cruz P., Jones F. S., Levin J. Use of prothrombin complex concentrates in the treatment of a hemophilic patient with an inhibitor of factor VIII. Blood 1976; 47: 983.
    PubMedGoogle Scholar
  • 41 Stenbjerg S., Jørgensen J. Activated F IX concentrate (FEIBA) used in the treatment of haemophilic patients with antibody to F VIII. Acta Med. Scand. 1978; 203: 471.
    PubMedGoogle Scholar
  • 42 Stenbjerg S., Tauris P., Skottun T., Jorgensen J. Total dental extraction in a patient with F VIII inhibitor. Thromb. Res. 1980; 18: 889.
    CrossrefPubMedGoogle Scholar
  • 43 Sultan Y., Brouet J. C., Debre P. Treatment of inhibitor to factor VIII with activated prothrombin concentrate. New Engl. J. Med. 1974; 291: 1087.
    PubMedGoogle Scholar
  • 44 Thomas W., Ionia McDonald D. Potency determination of anti-inhibitor coagulant complex - Autoplex. Haemostasis 1981; 10: 216.
    PubMedGoogle Scholar
  • 45 Vermylen J., Schetz J., Semeraro N., Mertens F., Verstraete M. Evidence that activated prothrombin concentrates enhance platelet coagulant activity. Brit. J. Haematol. 1978; 38: 235.
    CrossrefPubMedGoogle Scholar
  • 46 Vigano S., Cattaneo M., Gervasoni W., Mannucci P. M. Increased fibrinopeptide A after prothrombin complex concentrates. Thromb. Haemost. 1980; 44: 72.
    PubMedGoogle Scholar